CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for ...

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and ...

Novo Nordisk has announced that chief executive Lars Fruergaard Jørgensen will step down just days after the pioneering maker of obesity drugs cut its profit forecast. The Danish group said on Friday ...

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

When Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen dialed into a Teams video call with Chairman Helge ...

It would be another two years before French researchers would identify a retrovirus as the cause of AIDS, or acquired immunodeficiency syndrome, according to the CDC. It would be another three years ...

ParticipACTION will kick off its search for Canada's Most Active Community with the ParticipACTION Community Challenge presented by Novo Nordisk. ParticipACTION encourages everyone in Canada to get ...

Beyond 2 years, CABG with flow assessment was associated with a higher risk for new coronary angiography and new ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...